Wall Street brokerages expect that Syneos Health Inc (NASDAQ:SYNH) will post sales of $1.15 billion for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Syneos Health’s earnings, with the highest sales estimate coming in at $1.16 billion and the lowest estimate coming in at $1.14 billion. Syneos Health posted sales of $1.07 billion during the same quarter last year, which would suggest a positive year over year growth rate of 7.5%. The business is scheduled to report its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Syneos Health will report full year sales of $4.68 billion for the current year, with estimates ranging from $4.66 billion to $4.70 billion. For the next financial year, analysts expect that the business will report sales of $4.98 billion, with estimates ranging from $4.93 billion to $5.05 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Syneos Health.
Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.08. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Syneos Health had a return on equity of 9.55% and a net margin of 0.42%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.55 earnings per share.
Several research analysts have weighed in on SYNH shares. Zacks Investment Research upgraded Syneos Health from a “sell” rating to a “hold” rating in a report on Friday, May 24th. William Blair reiterated an “outperform” rating on shares of Syneos Health in a report on Tuesday, March 19th. Wolfe Research started coverage on Syneos Health in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a report on Saturday, March 30th. Finally, Credit Suisse Group lifted their target price on Syneos Health from $49.00 to $51.00 and gave the stock an “outperform” rating in a report on Tuesday, March 19th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $53.33.
SYNH stock opened at $47.12 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.02 and a current ratio of 1.02. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 17.98, a price-to-earnings-growth ratio of 1.64 and a beta of 1.41. Syneos Health has a 1-year low of $36.26 and a 1-year high of $56.34.
Institutional investors have recently modified their holdings of the company. Loomis Sayles & Co. L P lifted its holdings in shares of Syneos Health by 135.8% in the first quarter. Loomis Sayles & Co. L P now owns 500 shares of the company’s stock valued at $26,000 after purchasing an additional 288 shares in the last quarter. Enlightenment Research LLC bought a new stake in shares of Syneos Health in the fourth quarter valued at about $51,000. NumerixS Investment Technologies Inc bought a new stake in shares of Syneos Health in the fourth quarter valued at about $57,000. Bessemer Group Inc. bought a new stake in shares of Syneos Health in the fourth quarter valued at about $59,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Syneos Health in the first quarter valued at about $61,000.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Article: Different Types of Derivatives
Get a free copy of the Zacks research report on Syneos Health (SYNH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.